Fact Meets Function

Researchers investigated NAD concentration as a biomarker for personalizing nicotinamide mononucleotide (NMN) supplementation in humans. The study examined whether baseline NAD levels could predict individual responses to NMN treatment, potentially allowing tailored dosing strategies. This is human clinical evidence exploring the biological basis for individualized supplement approaches.

This randomized, double-blind, placebo-controlled clinical trial evaluated the efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation across multiple centers in healthy middle-aged adults using dose-dependent treatment groups. The study assessed both safety outcomes and efficacy measures, with findings specific to how NMN supplementation affected the study population at varying doses. This evidence represents a human clinical trial, the highest level of evidence for establishing effects in human populations.

This double-blind, placebo-controlled trial randomized 32 overweight or obese adults aged 55 to 80 to an oral beta-NMN formulation once or twice daily, or placebo, for 14 days, measuring NMN, NAD, and the NAD metabolome by mass spectrometry. The oral formulation was well tolerated and raised circulating NAD and related metabolites relative to placebo. It is one of the more rigorous human pharmacokinetic datasets on an oral NMN product. This is human safety and biomarker evidence, not a clinical outcomes study.

This human clinical study examined nicotinamide mononucleotide (NMN) as a potential intervention for anti-aging, longevity, and chronic disease management by investigating its effects on cellular metabolism and age-related conditions. The research found that NMN demonstrated effects on NAD+ metabolism pathways associated with aging processes and chronic disease states. This evidence is classified as human clinical research.

This human trial addressed a gap in the NMN literature: whether repeated daily oral doses at or above 1000 mg are safe in healthy adult men and women, which earlier clinical work had not reported. Participants took oral NMN and were monitored on standard safety measures. It extends the oral NMN safety record to higher repeated daily doses. This is human safety evidence and is not a study of clinical outcomes.

This placebo-controlled randomized human trial tested whether orally administered NMN raises blood NAD+ levels in healthy adults. Oral NMN was well tolerated and produced measurable increases in circulating NAD+ compared with placebo. The study addresses the absorption question directly: an oral dose changed the downstream blood marker it is supposed to change. This is human evidence on safety and blood levels, not a study of clinical outcomes or disease endpoints.

This human clinical trial gave 10 healthy men single oral doses of NMN at 100, 250, and 500 mg and tracked clinical parameters and nicotinamide metabolite pharmacokinetics over five hours. Oral NMN was safely metabolized without significant adverse effects, and metabolite levels rose in a dose-dependent way, indicating the oral dose was absorbed and processed. Ophthalmic examination and sleep quality assessment were also performed. This is early-phase human safety and pharmacokinetic evidence, not an efficacy study.